Key clinical point: BRCA carrier status alone should not influence screening recommendations for colorectal cancer or pancreatic ductal adenocarcinoma.

Major finding: Pancreatic ductal adenocarcinoma is generally recommended only for BRCA carriers only if they have a family history of the disease.

Study details: A clinical practice update for risk-based screening of colorectal and pancreatic cancer.

Disclosures: The investigators reported no conflicts of interest.